- Home
- CPRX vs PTY Comparison
CPRX vs PTY Comparison
Compare CPRX & PTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- PTY
- Stock Information
- Founded
- CPRX 2002
- PTY 2002
- Country
- CPRX United States
- PTY United States
- Employees
- CPRX N/A
- PTY N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- PTY Investment Managers
- Sector
- CPRX Health Care
- PTY Finance
- Exchange
- CPRX Nasdaq
- PTY Nasdaq
- Market Cap
- CPRX 2.6B
- PTY 2.6B
- IPO Year
- CPRX 2006
- PTY N/A
- Fundamental
- Price
- CPRX $20.59
- PTY $14.14
- Analyst Decision
- CPRX Strong Buy
- PTY
- Analyst Count
- CPRX 5
- PTY 0
- Target Price
- CPRX $33.20
- PTY N/A
- AVG Volume (30 Days)
- CPRX 1.5M
- PTY 550.4K
- Earning Date
- CPRX 08-06-2025
- PTY 01-01-0001
- Dividend Yield
- CPRX N/A
- PTY 9.65%
- EPS Growth
- CPRX 183.96
- PTY N/A
- EPS
- CPRX 1.65
- PTY N/A
- Revenue
- CPRX $558,499,000.00
- PTY N/A
- Revenue This Year
- CPRX $16.51
- PTY N/A
- Revenue Next Year
- CPRX $9.58
- PTY N/A
- P/E Ratio
- CPRX $12.45
- PTY N/A
- Revenue Growth
- CPRX 28.55
- PTY N/A
- 52 Week Low
- CPRX $19.00
- PTY $11.92
- 52 Week High
- CPRX $26.58
- PTY $14.88
- Technical
- Relative Strength Index (RSI)
- CPRX 48.79
- PTY 71.79
- Support Level
- CPRX $19.83
- PTY $13.93
- Resistance Level
- CPRX $21.82
- PTY $14.09
- Average True Range (ATR)
- CPRX 0.57
- PTY 0.04
- MACD
- CPRX 0.07
- PTY 0.01
- Stochastic Oscillator
- CPRX 45.33
- PTY 98.08
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About PTY Pimco Corporate & Income Opportunity Fund
PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.